XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
Trade Receivables
12 Months Ended
Dec. 31, 2023
Receivables [Abstract]  
Trade Receivables Trade Receivables
Product Sales
Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and RAPIVAB. At December 31, 2023 and 2022, receivables, net of reserves, related to sales of ORLADEYO were $54,149 and $41,508, respectively. A returns reserve related to sales of ORLADEYO of $288 was recorded as of December 31, 2023. No reserve or allowance amounts were recorded as of December 31, 2022 related to sales of ORLADEYO. At December 31, 2023 and 2022, receivables related to sales of RAPIVAB were $505 and $823, respectively. No reserve or allowance amounts were recorded as of December 31, 2023 and 2022, related to sales of RAPIVAB.
Collaborations
Receivables from collaborations were as follows (in thousands):
 December 31, 2023
 BilledUnbilled Total
Royalty receivables from partners$— $2,296 $2,296 
Total receivables from collaborators$— $2,296 $2,296 
 December 31, 2022
 BilledUnbilledTotal
U.S. Department of Health and Human Services, net$7,218 $284 $7,502 
Royalty receivables from partners741 — 741 
Other collaborations— 25 25 
Total receivables from collaborators$7,959 $309 $8,268 
As of December 31, 2023 and 2022, the reserve related to royalties from collaborations was not material.